Erectile Dysfunction Clinical Trial
— REVIVEOfficial title:
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in Subjects With Generalized Erectile Dysfunction
Verified date | June 2012 |
Source | VIVUS, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study is being conducted to compare the safety and efficacy of 3 doses of avanafil to placebo in men with mild to severe erectile dysfunction.
Status | Completed |
Enrollment | 646 |
Est. completion date | August 2009 |
Est. primary completion date | August 2009 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male subjects, age = 18 years; - Minimum 6 month history of mild to severe erectile dysfunction; - Subject is in a monogamous, heterosexual relationship for at least 3 months; - Subject agrees to make at least 4 attempts at intercourse per month; - Subject is willing and able to provide informed consent. Exclusion Criteria: - Allergy or hypersensitivity to PDE5 inhibitors; - History of dose-limiting AEs during therapy with a PDE5 inhibitor or hx of consistent treatment failure with other PDE5 inhibitors for therapy of ED; - Current or expected use of organic nitrates at any time during the study; - Previous or current antiandrogen therapy; - Use of prescription or over-the-counter drugs known to inhibit the activity of CYP3A4 at any time during the study; - Androgen replacement therapy that has not been stable for at least 3 month; - Initiation or change in dose of any alpha-blocker within 14 days prior to randomization; - ED as a result of spinal cord injury or radical prostatectomy; - Untreated hypogonadism or low serum total testosterone - History of or predisposition to priapism; - Any penile implant; - Elevated PSA, other evidence of prostate cancer, or previous radical prostatectomy; - History of any malignancy (except basal cell carcinoma or squamous cell carcinoma of the skin successfully treated by curative excision); - History of type 1 or type 2 diabetes; - Uncontrolled hypertension; - Hypotension; - Orthostatic hypotension; - Significant cardiovascular disease; - Abnormal ECG; - Hepatic or renal impairment; - Positive STD screen; - Clinically evident penile lesions, abrasions, or anatomical deformities; - Urinary tract or bladder infection; - Use of any treatment for erectile dysfunction other than study drug at any time during the study; - Participation in another investigational study within 30 days of screening or at any time during this study; - Previous participation in any other investigational study of avanafil; - History or current drug, alcohol, or substance abuse; - Any history of bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity or antidepressant use that has not been stable for at least 3 months; - Partners who are < 18 years of age, who are nursing, who are known to be pregnant at screening, who wish to become pregnant during the study period, who have any gynecologic problems or major medical conditions that would limit participation in sexual intercourse; - Evidence of any other condition by history, physical examination, or laboratory studies that, in the opinion of the investigator, would contraindicate the administration of study medication, affect compliance, interfere with study evaluations, limit study participation, contraindicate sexual activity, or confound the interpretation of study results. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Research Site | Albany | New York |
United States | Research Site | Atlanta | Georgia |
United States | Research Site | Atlanta | Georgia |
United States | Research Site | Bala Cynwyd | Pennsylvania |
United States | Research Site | Beachwood | Ohio |
United States | Research Site | Birmingham | Alabama |
United States | Research Site | Cary | North Carolina |
United States | Research Site | Charlotte | North Carolina |
United States | Research Site | Charlotte | North Carolina |
United States | Research Site | Clearwater | Florida |
United States | Research Site | Clearwater | Florida |
United States | Research Site | Coral Gables | Florida |
United States | Research Site | El Paso | Texas |
United States | Research Site | Harrisburg | North Carolina |
United States | Research Site | Hialeah | Florida |
United States | Research Site | Hickory | North Carolina |
United States | Research Site | Homewood | Alabama |
United States | Research Site | Houston | Texas |
United States | Research Site | Jacksonville | Florida |
United States | Research Site | Jacksonville | Florida |
United States | Research Site | Jupiter | Florida |
United States | Research Site | Kansas City | Missouri |
United States | Research Site | Lancaster | Pennsylvania |
United States | Research Site | Lawrenceville | New Jersey |
United States | Research Site | Madisonville | Kentucky |
United States | Research Site | New York | New York |
United States | Research Site | Ocala | Florida |
United States | Research Site | Pembroke Pines | Florida |
United States | Research Site | Raleigh | North Carolina |
United States | Research Site | Sacramento | California |
United States | Research Site | Salisbury | North Carolina |
United States | Research Site | San Diego | California |
United States | Research Site | San Diego | California |
United States | Research Site | Shreveport | Louisiana |
United States | Research Site | Spring | Texas |
United States | Research Site | Tampa | Florida |
United States | Research Site | Tucson | Arizona |
United States | Research Site | Waterbury | Connecticut |
United States | Research Site | Wichita | Kansas |
United States | Research Site | Wilmington | North Carolina |
United States | Research Site | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
VIVUS, Inc. |
United States,
Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, Didonato K, Trask B, Day WW. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012 Apr;9(4):11 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse | Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 3 "Did your erection last long enough for you to have successful intercourse?" | Baseline, 12 weeks | No |
Primary | Change in Percentage of Sexual Attempts in Which Subjects Were Able to Insert the Penis Into the Partner's Vagina | Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 2 "Were you able to insert your penis into your partner's vagina?" | Baseline, 12 weeks | No |
Primary | Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score | Questionnaire assesses subject's evaluation of erectile function over the previous 4-week period. Total score from questions 1-5 & 15 ranges from 1 to 30. A higher score indicates better erectile function. | Baseline, End of Treatment (up to 12 weeks) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 |